Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7
about
Identifying Recent HIV Infections: From Serological Assays to GenomicsA Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α4β7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVBottlenecks in HIV-1 transmission: insights from the study of founder virusesConstruction and characterization of highly infectious full-length molecular clones of a HIV-1 CRF07_BC isolate from Xinjiang, ChinaDifferences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder VirusCellular superspreaders: an epidemiological perspective on HIV infection inside the bodyThe V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentPredicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry.Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.Cryptic determinant of α4β7 binding in the V2 loop of HIV-1 gp120.The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Phenotypic properties of transmitted founder HIV-1Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.Transmitted/founder simian immunodeficiency virus envelope sequences in vesicular stomatitis and Semliki forest virus vector immunized rhesus macaques.Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialCharacterization of HIV-1 envelopes in acutely and chronically infected injection drug usersSelection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteinsInfection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopesEpitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivoGeneration and evaluation of clade C simian-human immunodeficiency virus challenge stocksHIV-1 target cells in the CNS.Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection.South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α ResistanceIntegrin α4β7 Expression Increases HIV Susceptibility in Activated Cervical CD4+ T Cells by an HIV Attachment-Independent Mechanism.Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in BotswanaHIV transmission biology: translation for HIV prevention.Differentiating founder and chronic HIV envelope sequences.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccinesMolecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clonesPostnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variantsTransmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
P2860
Q26778001-8CEDA1D7-43DB-4CAB-864A-EFDB9A385D3EQ27313287-3611816F-3F8E-4DA2-811A-4F07C6B9E12FQ27681527-04F33243-063D-493F-9B1A-71420BCC2B53Q28082862-9E15FBBC-D24B-4F4C-A6F2-355C189240BEQ28535848-32AED59E-CDD4-4235-8F34-752F2E0C9059Q28551914-8F443C63-B241-4BB7-8B7E-2FC89577C036Q28657772-1E2B6A1B-8D3C-4471-9A6F-8DDA5ADAF0A1Q30152923-7E42080F-2EE4-429D-933E-FE58F210740AQ30355260-B6620EA7-1246-405B-B95B-EBE356442F0DQ33638320-F17253AA-9725-4C0E-8214-D37A5BA20B4FQ33924420-E5A0F1CE-4FDF-465D-B412-76AD07D13E7DQ34059103-3C66606E-C550-4189-B83D-F2337C61DB78Q34270309-00435415-8E45-4728-AAAB-53F80274AC36Q34303849-AF9969AD-0D0F-4007-9F6A-1460761AB234Q34309493-541DF1AC-E85E-42C7-A585-E7732C2E0F6FQ34336058-E1BFB559-76E0-4C72-A424-ACFE1CBEC698Q34402934-1456B8F9-C072-433A-85E0-FE604F7C579EQ34433975-C5ED5081-92D9-45E6-9748-820782DF7B69Q34503200-664182EE-5115-4CD1-AF6B-D7322BE55ADDQ34562259-0A0624AD-26E5-4873-B3A9-D465E8230D69Q34620235-F2871F4C-225F-4EEA-B791-1577D70E8C0EQ34721189-58AA52BE-F308-4CC4-B2B6-23D897E51D30Q34791232-CDF652EA-18D9-4065-80A1-0095314F1907Q34907398-C4C7E5F7-E0A4-46EF-8E4C-F51F9C19D134Q35067233-08607440-F81C-42A2-B3AC-852ADAD0B2C1Q35115599-04EF80CB-9197-4421-A6CE-22A47C310D6AQ35196509-31CA86FA-5FC2-4727-A83C-72FB0C799B0AQ35219829-553581A5-E1E9-4EB3-88C1-743E390F2DD4Q35672336-5957871F-88D3-4576-AEB0-CD6C278F96BBQ35778333-8F338D58-F1A1-4A48-BD0C-E3038F0FE234Q35855028-F2579D1E-7018-4DC0-B174-FB6CF56F14C7Q35857404-C4CDD1D0-1959-425B-9C27-336F53BFDBD9Q36110367-82D76800-D36B-488F-B21F-F3DB057F846CQ36269097-B1276926-4550-4521-86F3-53DA94139D3AQ36277153-F2253CAB-3DE2-4EB6-8840-EC6D9987A5BFQ36298503-4FDC156E-B4D8-4059-A91A-C0A393ED7464Q36356350-FAA15CE2-3077-4CC5-B105-6F1D3549176CQ36532973-59C83864-F053-4980-9961-82711A1C71DFQ36588632-159F8E3D-3AA9-41C6-B369-197CF33C6E4EQ36607127-08148731-3442-4103-8504-04CCA9B3488C
P2860
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Transmitted/founder and chroni ...... by blocking the integrin α4β7
@ast
Transmitted/founder and chroni ...... by blocking the integrin α4β7
@en
type
label
Transmitted/founder and chroni ...... by blocking the integrin α4β7
@ast
Transmitted/founder and chroni ...... by blocking the integrin α4β7
@en
prefLabel
Transmitted/founder and chroni ...... by blocking the integrin α4β7
@ast
Transmitted/founder and chroni ...... by blocking the integrin α4β7
@en
P2093
P2860
P50
P1433
P1476
Transmitted/founder and chroni ...... by blocking the integrin α4β7
@en
P2093
Amit Kumar
Bhavna Hora
Charl Coleman
Christina Ochsenbauer
Erica H Parrish
Haitao Ding
Jennifer Hopper
Jennifer M Pfaff
P2860
P304
P356
10.1371/JOURNAL.PPAT.1002686
P50
P577
2012-05-31T00:00:00Z